AlloVir Analyst Ratings
AlloVir Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 08/18/2023 | 588.26% | B of A Securities | → $17 | Initiates Coverage On | → Buy |
| 08/07/2023 | 709.72% | Morgan Stanley | $20 → $20 | Reiterates | Overweight → Overweight |
| 04/26/2023 | 669.23% | SVB Securities | $16 → $19 | Maintains | Outperform |
| 01/27/2023 | 709.72% | Morgan Stanley | $27 → $20 | Maintains | Overweight |
| 01/23/2023 | 669.23% | SVB Leerink | $25 → $19 | Maintains | Outperform |
| 11/07/2022 | 912.15% | SVB Leerink | $24 → $25 | Maintains | Outperform |
| 09/09/2022 | 993.12% | Morgan Stanley | $32 → $27 | Maintains | Overweight |
| 07/28/2022 | 831.17% | SVB Leerink | $30 → $23 | Maintains | Outperform |
| 05/19/2022 | 1276.52% | Piper Sandler | $55 → $34 | Maintains | Overweight |
| 02/10/2022 | 1114.57% | SVB Leerink | $32 → $30 | Maintains | Outperform |
| 01/18/2022 | 1721.86% | Morgan Stanley | $48 → $45 | Maintains | Overweight |
| 12/17/2021 | 1195.55% | SVB Leerink | $37 → $32 | Maintains | Outperform |
| 11/08/2021 | 1397.98% | SVB Leerink | $41 → $37 | Maintains | Outperform |
| 10/12/2021 | 1843.32% | Morgan Stanley | $47 → $48 | Maintains | Overweight |
| 09/29/2021 | 9009.31% | Morgan Stanley | $175 → $225 | Maintains | Overweight |
| 08/18/2021 | 1802.83% | Morgan Stanley | $50 → $47 | Maintains | Overweight |
| 05/06/2021 | 1600.4% | SVB Leerink | $41 → $42 | Maintains | Outperform |
| 04/19/2021 | 1924.29% | Morgan Stanley | $49 → $50 | Maintains | Overweight |
| 08/24/2020 | 1924.29% | JP Morgan | → $50 | Initiates Coverage On | → Overweight |
| 08/24/2020 | 1883.81% | Morgan Stanley | → $49 | Initiates Coverage On | → Overweight |
| 08/24/2020 | 1559.92% | SVB Leerink | → $41 | Initiates Coverage On | → Outperform |
| 日期 | 上行/下行 | 分析公司 | 目標價格變化 | 評級變化 | 上一次/當前評級 |
|---|---|---|---|---|---|
| 2023年08月18日 | 588.26% | B of A證券 | →$17 | 開始承保 | →購買 |
| 08/07/2023 | 709.72% | 摩根士丹利 | $20→$20 | 重申 | 超重→超重 |
| 04/26/2023 | 669.23% | SVB證券 | $16→$19 | 維護 | 跑贏大盤 |
| 2023年1月27日 | 709.72% | 摩根士丹利 | $27→$20 | 維護 | 超重 |
| 2023年1月23日 | 669.23% | SVB Leerink | $25→$19 | 維護 | 跑贏大盤 |
| 11/07/2022 | 912.15% | SVB Leerink | $24→$25 | 維護 | 跑贏大盤 |
| 09/09/2022 | 993.12% | 摩根士丹利 | $32→$27 | 維護 | 超重 |
| 07/28/2022 | 831.17% | SVB Leerink | $30→$23 | 維護 | 跑贏大盤 |
| 2022年05月19日 | 1276.52% | 派珀·桑德勒 | $55→$34 | 維護 | 超重 |
| 02/10/2022 | 1114.57% | SVB Leerink | $32→$30 | 維護 | 跑贏大盤 |
| 01/18/2022 | 1721.86% | 摩根士丹利 | $48→$45 | 維護 | 超重 |
| 2021/12/17 | 1195.55% | SVB Leerink | $37→$32 | 維護 | 跑贏大盤 |
| 11/08/2021 | 1397.98% | SVB Leerink | $41→$37 | 維護 | 跑贏大盤 |
| 10/12/2021 | 1843.32% | 摩根士丹利 | $47→$48 | 維護 | 超重 |
| 09/29/2021 | 9009.31% | 摩根士丹利 | $175→$225 | 維護 | 超重 |
| 2021/08/18 | 1802.83% | 摩根士丹利 | $50→$47 | 維護 | 超重 |
| 05/06/2021 | 1600.4% | SVB Leerink | $41→$42 | 維護 | 跑贏大盤 |
| 04/19/2021 | 1924.29% | 摩根士丹利 | $49→$50 | 維護 | 超重 |
| 08/24/2020 | 1924.29% | 摩根大通 | →$50 | 開始承保 | →超重 |
| 08/24/2020 | 1883.81% | 摩根士丹利 | →$49 | 開始承保 | →超重 |
| 08/24/2020 | 1559.92% | SVB Leerink | →$41 | 開始承保 | →跑贏大盤 |
What is the target price for AlloVir (ALVR)?
AllVir(ALVR)的目標價是多少？
The latest price target for AlloVir (NASDAQ: ALVR) was reported by B of A Securities on August 18, 2023. The analyst firm set a price target for $17.00 expecting ALVR to rise to within 12 months (a possible 588.26% upside). 7 analyst firms have reported ratings in the last year.
A銀行證券於2023年8月18日報告了allVir(納斯達克：ALVR)的最新目標價。這家分析公司將目標價定為17美元，預計平均資產收益率將在12個月內升至(可能上漲588.26%)。去年有7家分析公司公佈了評級。
What is the most recent analyst rating for AlloVir (ALVR)?
AllVir(ALVR)的最新分析師評級是多少？
The latest analyst rating for AlloVir (NASDAQ: ALVR) was provided by B of A Securities, and AlloVir initiated their buy rating.
納斯達克(Sequoia Capital：ALVR)的最新分析師評級是由美國銀行證券提供的，allVir啟動了他們的買入評級。
When is the next analyst rating going to be posted or updated for AlloVir (ALVR)?
AlloVir(ALVR)的下一次分析師評級將於何時發佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of AlloVir, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for AlloVir was filed on August 18, 2023 so you should expect the next rating to be made available sometime around August 18, 2024.
分析師在進行了廣泛的研究後得出了股票評級，其中包括查閱公共財務報表，與阿洛維爾的高管和客戶交談，以及聽取收益電話會議。大多數分析師每三個月就會這樣做一次，所以你每年應該會得到每家公司每家公司的4個評級。AllVir的上一次評級是在2023年8月18日提交的，所以你應該預計下一次評級將在2024年8月18日左右提供。
Is the Analyst Rating AlloVir (ALVR) correct?
分析師對AllVir(ALVR)的評級正確嗎？
While ratings are subjective and will change, the latest AlloVir (ALVR) rating was a initiated with a price target of $0.00 to $17.00. The current price AlloVir (ALVR) is trading at is $2.47, which is within the analyst's predicted range.
雖然評級是主觀的，並將發生變化，但最新的allVir(ALVR)評級是以0.00美元至17.00美元的目標價啟動的。目前的價格為2.47美元，在分析師的預測範圍內。